Fig. 2From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC resultsStudy flow chart. HER2 ISH results at the time of diagnosis were available in 26 patients (2 patients with HER2 IHC 1+, 21 patients with 2+, and 3 patients with 3+ disease) with a median HER2/CEP17 ratio of 3.23 (ranged 1.6–8.89)Back to article page